GPCR Stock Analysis: Buy, Sell, or Hold?
GPCR - Structure Therapeutics Inc. American Depositary Shares
$49.09
-1.43 (-2.83%)
âŧ
5d:
-9.94%
30d:
-3.37%
90d:
+26.55%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When GPCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GPCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GPCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: GPCR is currently trading at $49.09, which is considered fair relative to its 30-day fair value range of $48.24 to $53.18.
Technical Outlook: Technically, GPCR is in a uptrend. The price is currently testing key support at $49.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GPCR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.77 (+113.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GPCR is in a uptrend. The price is currently testing key support at $49.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GPCR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.77 (+113.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$48.24 -
$53.18
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 113.4% below Wall St target ($104.77)
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$48.24 -
$53.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$49.01
Resistance Level
$55.60
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.45
Wall Street Target
$104.77
(+113.4%)
Share & Embed Analysis
Last updated: August 22, 2026 6:24 PM ET
Data refreshes hourly during market hours. Next update: 7:24 PM
Data refreshes hourly during market hours. Next update: 7:24 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GPCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
